Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

25 June 2008 CSL Behring Awards LEAD Grants to Support Patient Group Advocacy Efforts

CSL Behring announced it has recently awarded seven grants totaling more than $90,000 to patient advocacy organizations in the United States. The seven grants represent the first round of awards in the company's Local Empowerment for Advocacy Development (LEAD) program. CSL Behring is a global leader in the plasma protein biotherapeutics industry. LEAD grants support grassroots advocacy efforts by organizations committed to helping people with rare diseases who use plasma-derived and recombinant therapies to manage their health conditions. CSL Behring awards LEAD grants semiannually.

> Read More
03 June 2008 CSL Behring Study Shows Extended Half-life Recombinant VIIa Leads to Longer Biologic Activity

CSL Behring today presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.

> Read More
03 June 2008 CSL Behring Awards Global Grants to Next Generation of Coagulation Researchers

CSL Behring, a global leader in the protein biotherapeutics industry, today awarded CSL Behring - Prof. Heimburger Award grants to five young medical researchers at the Hemophilia 2008 World Congress of the World Federation of Hemophilia (WFH).

> Read More
17 May 2008 Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease

Melissa Biggs, a fashion designer and actress who appeared on Baywatch was recently named spokesperson for an education campaign on behalf of CSL Behring, and is urging Americans to get tested for alpha1 antitrypsin (AAT) deficiency after her own diagnosis with the condition in 2005.

> Read More
17 April 2008 CSL Behring Submits NDS to Health Canada Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema

CSL Behring has filed a new drug submission (NDS) with Health Canada seeking approval to market its C1-esterase inhibitor concentrate in Canada for the treatment of hereditary angioedema (HAE), a rare and serious genetic disorder. The submission is based on the recently completed phase II/III prospective, double-blind placebo-controlled International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T.), the largest HAE trial ever conducted, that studied the efficacy of pasteurized C1-INH concentrate.

> Read More
Page 51 of 54 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+